Omnihealth Practice

HEMATOLOGY

Bridging towards allogeneic stem-cell transplant with the early use of novel therapies in the relapsed/refractory acute lymphoblastic leukemia setting

12 Aug 2021

Balancing efficacy and cardiovascular safety in chronic lymphocytic leukemia with acalabrutinib

03 Aug 2021

The real-world use of ixazomib achieved stable disease for nearly 3 years, longer than in clinical trial

24 Mar 2021

Real-world analysis found ixazomib triple therapy effective in the management of relapsed/refractory multiple myeloma

28 Feb 2021

Denosumab as a well-tolerated and effective bone targeting treatment option for multiple myeloma patients with osteolytic lesions

31 Dec 2020

Brentuximab vedotin serves as a viable option to combine with chemotherapy for advanced stage Hodgkin lymphoma

31 Dec 2020

Bruton’s tyrosine kinase inhibitors delay disease progression and extend survival in patients with relapsed/refractory mantle cell lymphoma

30 Dec 2020

Recent advances in management of chronic lymphocytic leukemia patients with a novel kinase inhibitor

29 Oct 2020

The use of daratumumab in multiple myeloma: Developing novel immunotherapy strategies to prolong survival

31 Aug 2020

Advanced-stage Hodgkin lymphoma in an elderly patient: A case report highlighting the efficacy of brentuximab vedotin treatment

30 Jun 2020

Denosumab as a well-tolerated and effective bone targeting treatment option for multiple myeloma patients with osteolytic lesions

Multiple myeloma (MM) is a plasma cell malignancy with approximately 150,000 new cases globally each year.¹ In 2016, approximately 270 new cases were reported in Hong Kong.¹ As the second most frequent hematological disease worldwide, MM accounts for 0.9% of all new cancer cases and 1.1% of all canc

31 Dec 2020

Dr. Wong, Siu-Ming Raymond

Head of Division of Haematology,
Department of Medicine & Therapeutics,
Faculty of Medicine,
The Chinese University of Hong Kong

Brentuximab vedotin serves as a viable option to combine with chemotherapy for advanced stage Hodgkin lymphoma

The combination treatment approach of chemotherapy and radiotherapy has significantly improved the survival outcomes of patients with Hodgkin lymphoma (HL) over the past several decades.¹ Whereas the conventional frontline therapies, such as ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), c

31 Dec 2020

Dr. Law, Man-Fai

Division of Haematology,
Department of Medicine & Therapeutics,
Prince of Wales Hospital,
Hong Kong

NDF 2021

March 13, 2021 |

Hong Kong

Balancing efficacy and cardiovascular safety in chronic lymphocytic leukemia with acalabrutinib

HEMATOLOGY

03 Aug 2021

Dr. John C. Byrd

D. Warren Brown Chair of Leukemia Research,
The Ohio State University
Comprehensive Cancer Center,
United States

Dr. Jeff P. Sharman

Director of Research,
Willamette Valley Cancer Institute and
Medical Director of Hematology Research,
The United States Oncology Network,
United States

Bridging towards allogeneic stem-cell transplant with the early use of novel therapies in the relapsed/refractory acute lymphoblastic leukemia setting

Complete remission (CR) is a prerequisite to allogenic stem-cell transplant (allo-SCT) which remains to be the only curative option in adult with relapsed/refractory acute lymphoblastic leukemia (R/R ALL).¹ However, conventional cytotoxic chemotherapies can only achieve CR in 40-50% of adult ALL pat

12 Aug 2021

Prof. Tse, Wai-Choi Eric

Clinical Professor,
Department of Medicine,
Li Ka Shing Faculty of Medicine,
The University of Hong Kong

Unexpectedly high risk of childhood leukemia associated with Down syndrome

Children with Down syndrome are at an elevated risk of multiple malignancies and hematological disorders such as different types of leukemia.1,2 To better reflect the current risk association between Down syndrome and childhood leukemia, investigators from the United States had conducted a large, co

29 Jun 2021

Novel disease-risk stratification system provides a finer prediction of survival following stem-cell transplantation for patients with hematologic malignancies

Hematologic malignancy is the 10^th most common cancer in Hong Kong with more than 1,000 new cases diagnosed each year.¹ While most of the other cancers affect mainly old people, sufferers of hematologic malignancies can be at any age from newborns to the elderly.¹ Although there is a broad range of

09 Apr 2021